Related to RuiYi Licenses mAb Development to China's Genor

• DNA Methylation Rules: Studying Epigenetics with New Tools
  The tools to unravel the epigenetic control mechanisms that influence how cells control access of transcriptional proteins to DNA are just beginning to emerge.
  
• Stockholm-Uppsala Region Ups the Ante
  The region bets big in the quest for international renown.
  
• Women and Smoking
  Looking for a reason to quit, ladies? Look no further.
  
• Bird Flu Back Again?
  H7N9 has killed six people so far. Find out what’s being done about it.
  
• Poland Invests in Biotech Infrastructure
  Will it be enough for the industry to succeed?
  
• Performing “Informative Clinical Trials” in Mice
  Patient-derived tumor xenografts: better than cancer cell lines for preclinical testing in animal models?
  
• Cancer Model Database Emerges from WOMB
  Oncology researchers wishing for a tool to help them find available models and services may have had their prayers answered.
  
• Detecting Acquired Drug Resistance in Cancer
  New methods allow noninvasive analysis in blood plasma.
  
• The Tumor Microenvironment as a Drug Target: Chasing Slippery Targets
  This first part of a two-part series discusses how researchers are looking at ways to attack tumors by targeting the cellular frameworks that keep them alive.
  
• The Tumor Microenvironment as a Drug Target, Part II
  In the search for new targets, cancer researchers are taking a closer look at the cellular support networks that allow tumors to survive.
  
• Literature Review: A Step Closer to Personalized Medicine
  Researchers use patient-specific cell lines derived in mice to personalize chemotherapy.
  
• Moving Genomics Closer to the Clinic
  Foundation Medicine and Memorial Sloan-Kettering Cancer Center are working to translate genomic information into personalized cancer treatment.
  
• GEN Exclusive: 2009 Laskers Honor Advances in Stem Cell Technology and Cancer Therapy
  Work cited will revolutionize cancer therapy and impact a potential $700 million global stem cell market.
  
• 2009 in Review: Headline-Making Stories in the Biotech Industry
  Even though last year was marred by the economic crash, the life science sector showed significant progress.
  
• Roche Takes a Stab at Getting mAbs Under the Skin
  Firm is testing Herceptin SC in Phase III and expects to couple it with a user-friendly delivery device.
  
• Antibody-Drug Conjugates to Fight Cancer
  While mAbs have been extremely successful, these empowered antibodies are touted as the next big blockbusters.
  
• Asia-Pacific’s March toward a New Drug Development Paradigm
  Increasing investment, embracing new R&D models, and aligning regulatory agencies are key to the region’s success.
  
• Asia’s Emerging Markets Catching Up to the U.S. and Europe in Terms of Innovation
  Countries like China and Korea are growing to be more than just manufacturing hubs.
  
• For Some Emerging Companies, the Road to Growth Connects the U.S. and China
  While American firms are tapping China’s size and regulatory path, Chinese biotechs are going west for money and expertise.
  
• Literature Review: Which Drug Combination Will Unlock Triple-Negative Breast Cancer?
  Researchers describe a strategy for treating TNBC that combines noncompetitive antibodies to achieve degradation of EGFR and tumor inhibition.